2.7.3. Assessment of outcomes.
obesity, comorbidity, bleeding, chronic pulmonary disease, lymphoma, depression, psychoses, paralysis, alcohol abuse, valvular disease, Comorbidity, peptic ulcer disease, rheumatoid, drug abuse, hypertension, weight loss, AIDS/HIV infection, diabetes
OBESITY, BLEEDING, PERIPHERAL VASCULAR DISORDER, OTHER NEUROLOGICAL DISORDERS, FLUID AND ELECTROLYTE DISORDERS, VASCULAR DISEASES, CHRONIC PULMONARY DISEASE, HYPOTHYROIDISM, DIABETES, RENAL FAILURE, METASTATIC CANCER, CONGESTIVE HEART FAILURE, COAGULOPATHY, PEPTIC ULCER DISEASE, COMPLICATIONS, CARDIAC ARRHYTHMIAS, METASTASIS, BLOOD LOSS ANEMIA, DISEASE, LIVER DISEASE, SOLID TUMOR, PULMONARY CIRCULATION DISORDER, LYMPHOMA, HYPERTENSION, DEFICIENCY ANEMIA
The principal investigator collected the baseline information of the patients and recorded them in a pre-designed questionnaire. This information included age, gender, height, weight, BMI, marital status, educational level, occupation, smoking, disease duration, fall history within the past year, affected knees, grade, analgesics, cartilage drug, and comorbidity. We counted the comorbidities according to the Elixhauser Comorbidity Index. These were congestive heart failure, cardiac arrhythmias, valvular disease, pulmonary circulation disorders, peripheral vascular disorders, hypertension (uncomplicated), hypertension (complicated), paralysis, other neurological disorders, chronic pulmonary disease, diabetes (uncomplicated), diabetes (complicated), hypothyroidism, renal failure, liver disease, peptic ulcer disease (excluding bleeding), AIDS/HIV infection, lymphoma, metastatic cancer, solid tumor without metastasis, rheumatoid arthritis/collagen vascular diseases, coagulopathy, obesity, weight loss, fluid and electrolyte disorders, blood loss anemia, deficiency anemia, alcohol abuse, drug abuse, psychoses, and depression. The complications of both study groups were documented at 2 and 3 months.